SCI Fellowship Awards
In keeping with its core mission, the SCI offers Innovation Awards to support projects focused on the acceleration of basic, translational, clinical and population-based cancer research, and projects focused on specific types of cancer, such as pancreatic, breast, gynecologic and sarcoma cancers.
Stanford Cancer Institute Nodal Grant Awards ($50,000)
The SCI seeks to increase the number of clinical, laboratory, and population researchers, who are carrying out cancer research with applicability to the basic biology, prevention, diagnosis or treatment of cancer, or to the quality of life of cancer patients. This critical source of funding enables trainees to achieve faculty positions and obtain career development awards. We strongly encourage candidates of diverse backgrounds to apply.
The RFA is open to individuals who are completing their clinical or post-doctoral training and are pursuing clinical, laboratory, or population-based research projects with direct cancer relevance at Stanford University. These individuals are in the final year of their residency and planning to look for faculty positions in the next year.
The most important criteria for the fellowship awards are that applicants:
- Have clear evidence of intent to pursue an academic career (prior research experience is a plus).
- Have a commitment to apply during the 2023 academic year for outside support from foundations, the NIH, or other sources. If outside support is obtained for the 2023 academic year while the application is reviewed and approved, it will be used to offset the SCI funds awarded
SUBMISSION DEADLINE: Closed
2022 SCI Fellowship Awardees
Maria Angulo-Ibanez, PhD, is a postdoctoral fellow in the laboratory of Dr. Katrin Chua, where she studies the molecular mechanisms and physiologic functions of the Sirtuin gene SIRT7 at the intersection of cancer and aging biology. Dr. Angulo-Ibanez obtained her PhD in Immunology at the University of Barcelona, Spain. Her research interests center around fundamental cancer research. As a graduate student, Dr. Angulo-Ibanez studied the function of ERK5, a MAP kinase, in genome integrity maintenance and hematopoiesis. She discovered that the absence of Erk5 impairs hematopoietic development through the deregulation of intracellular dNTP pools. Moreover, Erk5 loss facilitates tumor development in Atm-deficient mice.
Gladys Rodriguez, MD, is a hematology/oncology fellow at Stanford University School of Medicine with a clinical focus on gastrointestinal malignancies. She has an impressive clinical training background, including an Internal Medicine residency at the University of California San Francisco, followed by her subspecialty training at Stanford in Hematology and Oncology. An overarching goal of her career is to develop scalable interventions grounded in theory and evidence to overcome inequities in cancer outcomes. Dr. Rodriguez proposes developing and testing a promising approach to overcome cancer inequities among low-income Latinx adults with cancer, focusing on precision medicine
Jason Ross, MD, PhD, is a Kaplan Research Fellow in the Department of Radiation Oncology at Stanford University. He completed his undergraduate training at Stanford University, where he majored in biological sciences and conducted research in stem cell biology. His current research is focused on the influence of radiotherapy on the tumor-immune microenvironment. Dr. Ross intends to continue studying how radiation affects tissues and tumors at the molecular level to modulate the radiobiological response of normal and malignant cells in order to improve the therapeutic index of radiation therapy.
Qian Yin, PhD, is an instructor in the Institute of Immunity, Transplantation, and Infection at Stanford University. Her research interest lies at the interface of materials science and immunology. She is focused on employing an engineering-centric approach to elucidate the key immune pathways for driving anti-tumor immunity. An overarching goal of Dr. Yin’s career is to leverage her expertise in polymer chemistry, materials science, nanotechnology, and immunology to address the critical challenges in cancer therapy and ultimately translate the new materials or technologies into clinical applications.
The SCI has funded the Fellowship Awards dating back to 2014. A list of funded projects prior to 2020 is available upon request.
Dr. Crossley is a postdoctoral fellow in the laboratory of Dr. Karlene Cimprich, a member of the SCI and the Chemical and Systems Biology Department. Dr. Crossley has a longstanding interest in how RNA and transcription influence the processes that maintain the stability of our genome. Deregulation of these processes leads to increased levels of DNA damage and genome instability, which are hallmarks of cancer. Increasingly, genome instability is also recognized as a vulnerability of cancer cells that can be exploited therapeutically. It is therefore critical to have a deep mechanistic understanding of how genome instability arises in cells, which has been a strong motivation in Dr. Crossley’s research.
Dr. Lo is a postdoctoral fellow in Dr. Calvin Kuo’s laboratory. Dr. Lo is interested to understand the control of gastrointestinal and cancer stem cell biology, especially how critical intrinsic genetic mutations and extrinsic extracellular components within the microenvironment influence cell behaviors. Stem cells of the gastrointestinal tract give rise to the surface lining of the epithelium and must continuously produce new cells to replace those shed into the lumen throughout the lifespan. When mutations accumulate in these stem cells, they can grow uncontrollably into benign polyps or malignant tumors. Dr. Lo has focused his efforts on establishing next-generation CRISPR/Cas9 genome editing tools and applying them to gain insight into how different signaling pathways can contribute to gastrointestinal stem cell activity and tumorigenesis.
Dr. Soji is a radiation oncology resident who studies the mechanisms underlying natural killer (NK) cell exclusion in solid tumors. He is interested in increasing the therapeutic index of radiation therapy using small molecules and biological agents. This interest started during his undergraduate studies, where he focused on the targeted delivery of chemotherapeutic agents using tamoxifen. He subsequently enrolled in a medical scientist training program and completed his doctoral thesis in medicinal chemistry, where he designed, synthesized, characterized and tested novel histone deacetylase (HDAC) inhibitors which are known to radiosensitize tumors. Currently, he is investigating the role of the innate immune system in cancer, particularly the mechanism of NK cell migration in the tumor microenvironment, under the mentorship of Quynh Le, MD. Dr. Sodji intends to continue onward in this novel area of research in radiation oncology and cancer biology as a physician-scientist.
Dr. Tang’s research career has been focused on translating advanced biomedical knowledge into therapeutic strategies. Through his postdoctoral training in Dr. Monte Winslow’s laboratory, Dr. Tang has acquired a unique set of skills that will allow him to apply molecular, cellular biology and mouse models to study human cancer. Metastasis is a major clinical challenge driven by poorly understood cell state alterations. By incorporating increasingly quantitative methods and powerful in vivo methods, Dr. Tang intends to uncover general rules that govern tumor progression and metastatic spread and discover novel therapeutic targets across the continuum of cancer progression, including the lethal metastatic stage.
Dr. Vogel is a postdoctoral fellow at the Stanford Prevention Research Center in the Department of Medicine and is supported by a fellowship award from the Tobacco-Related Disease Research Program. As a social psychologist, Dr. Vogel considers experimental research imperative for understanding health behaviors and empowering individuals to improve their quality of life and reduce their cancer risk. Tobacco use is among the leading causes of cancer worldwide. Dr. Vogel’s current research program aims to understand the influence of social media on young people’s tobacco use and develop digital interventions for tobacco and other substance use. Long-term, she aims to establish an independent academic research career in cancer prevention, using digital tools to address young people’s tobacco use and other addictive behaviors.
Corinne Beinat, PhD
Corinne Beinat, PhD completed her doctoral training in medicinal chemistry and pharmacology and has since utilized these skills to expand her research in the fields of molecular imaging and cancer biology. She studies the development of novel small molecule radiotracers and evaluation of biomarkers for the molecular imaging of tumor biology. While working in the laboratory of Sam Gambhir, MD, PhD, she synthesized and evaluated a novel positron emission tomography (PET) radiotracer, [18F]DASA-23, which provides a measure of aberrantly expressed pyruvate kinase M2 (PKM2) in glioblastoma. PKM2 regulates brain tumor metabolism, a key factor in glioblastoma growth. Due to the promising results obtained, this radiotracer was recently translated to the clinic and is now being studied in patients with intracranial malignancies at Stanford.
Graham Erwin, PhD
Postdoctoral Research Fellow, Genetics
Graham Erwin, PhD, is a postdoctoral research fellow who is interested in repetitive DNA sequences, known as long tandem-repeat (TR) sequences. As a graduate student, he developed a new class of synthetic transcription factors which regulate a critical step of transcription. His vision is to combine his graduate work creating new chemical tools to target repetitive DNA sequences with his postdoctoral work in cancer genomics. He is mining cancer genomes for mutations in TRs. His research in the laboratory of Michael Snyder, PhD, aims to study how TR sequences impact cancer biology and harness that information to devise new precision-targeted therapies that target these DNA sequences.
Zinaida Good, PhD
Postdoctoral Research Fellow, Stanford Cancer Institute
Zinaida Good, PhD, is a postdoctoral fellow who is training under Crystal L. Mackall, MD, and Sylvia K. Plevritis, PhD. Her research is focused on investigating how chimeric antigen receptor (CAR)-expressing T lymphocytes succeed or fail in patients, in order to guide the design of the next generation of engineered cell therapies. Her projects include: (1) identification of CAR T-cell populations that are associated with durable complete response in diffuse large B-cell lymphoma (DLBCL) patients receiving a CD19-targeted therapy Axicabtagene ciloleucel; (2) defining features of successful CAR T-cell clones in DLBCL patients receiving bispecific CD19/CD22-targeted CAR T cells on a Stanford trial; and (3) identifying modulation points to improve CAR T-cell function within the tumor microenvironment in DLBCL and solid tumors. Her goal is to utilize innovative single-cell analysis methods and advanced algorithms to identify promising immunotherapy strategies for patients with cancer.
SUBMISSION DEADLINE: Closed